Non-Interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

This study is currently recruiting participants.

Verified by AstraZeneca, December 2007

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00573222

Purpose

This is a 3-month non-interventional, observational study on patients with moderate and severe asthma.

Condition	Intervention
Asthma	Drug: Symbicort

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

Study Type:	Observational
Study Design:	Prospective
Official Title:	Non-Interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

To evaluate & describe asthma control in adult patients w/moderate to severe asthma treated w/Symbicort SMART following the frequency, type & severity of symptoms through the Asthma Control Questionnaire.

Secondary Outcome Measures:

to evaluate the safety of Symbicort SMART treatment through the number and type of reported adverse events 2. assessment of patient's satisfaction with the treatment 3.assessment of physician's satisfaction with the treatment

Estimated Enrollment:	400
Study Start Date:	November 2007

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573222

Contacts

Contact: AstraZeneca Croatia Clinical Study, Information

+385 1 4628 002

Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Anan Marija Gjurovic

AstraZeneca

More Information

Study ID Numbers:	NIS-RHR-SYM-2007/1
Study First Received:	December 13, 2007
Last Updated:	December 13, 2007
ClinicalTrials.gov Identifier:	NCT00573222
Health Authority:	Not Required:

Keywords provided by AstraZeneca:

Asthma

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases

Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Immune System Diseases
Bronchial Diseases

Therapeutic Uses
Anti-Asthmatic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009